Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeuroDerm Makes Progress On Simplified Path To Parkinson's Approval

Executive Summary

NeuroDerm Ltd. reported Phase II results for its drug-device combination product ND0612 that reinforce its ability to fill a gap in the treatment of advanced Parkinson's disease, and it could be on the market in the US in less than three years if the company is able to stay on its revised development path.

You may also be interested in...



Deal Watch: Takeda Continues Transaction Spree With Four More Deals

Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.

Bioequivalence To Duopa Could Mean Quick Path To Market For NeuroDerm In Parkinson’s

With several companies working on new Parkinson’s therapies to maintain therapeutic levels of levodopa, NeuroDerm thinks it has a formulation that will offer similar benefits to AbbVie’s Duopa, with less invasive therapy.

NeuroDerm takes rollercoaster ride on Parkinson's results

Investors took NeuroDerm on a rollercoaster ride the last two days of 2014 – first driving shares up as high as 208.5% on 30 December, only to back away from the stock on 31 December, with shares falling 26%.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel